Drug Approval | October 18, 2021
U.S. FDA approves Roche’s Tecentriq as adjuvant treatment for small cell lung cancer
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
VIPER AI solutions support care teams by automating the identification of potentially eligible patients at the time of diagnosis and easily matching them to relevant trials
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
Torrent is one of India's fastest-growing pharma majors
Subscribe To Our Newsletter & Stay Updated
